The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,480,239 in first-year total cost, median $376,468.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BCMB-G (10)]1
- Special Emphasis Panel[ZRG1 ETTN-M (11)]1
- Special Emphasis Panel[ZRG1 ETTN-P (13)]1
Most frequent institutions
- BIOINVENU CORPORATION2
- CONFOMETRX, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Novel tools for investigating GPCR-mediated 14-3-3 signaling pathway2R44MH108203-02 | EISHINGDRELO, HAIFENG | BIOINVENU CORPORATION, NJ | $773,235 | ZRG1 |
| 2017 | Structure-based discovery of dopamine D1 receptor selective small molecule ligands1R44MH112215-01 | FENG, DANFISH, INBARSUN, BINGFA | CONFOMETRX, INC., CA | $376,468 | ZRG1 |
| 2016 | Novel tools for investigating GPCR-mediated 14-3-3 signaling pathway1R43MH108203-01A1 | EISHINGDRELO, HAIFENG | BIOINVENU CORPORATION, NJ | $330,536 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.